CYTOF
Altamira Therapeutics Ltd

25,077
Mkt Cap
$287,488.00
Volume
141.00
52W High
$0.1478
52W Low
$0.0501
PE Ratio
-0.04
CYTOF Fundamentals
Price
$0.0502
Prev Close
$0.0503
Open
$0.0502
50D MA
$0.0922
Beta
0.84
Avg. Volume
4,549.55
P/B
0.07
Loading...
Loading...
Poll

Earnings Recap

Altamira expects its operating expenses to decrease significantly in 2026, following the planned spin-off of its ATAG subsidiary and termination of US SEC reporting duties, with updated guidance to follow.

Bullish

Altamira significantly reduced its net loss and operating loss, expanded its nucleic acid delivery platform with new applications, and saw its associate achieve key regulatory approvals and a milestone payment.

Bearish

Altamira experienced a significant decrease in shareholders' equity and a substantial increase in current liabilities, including new loans, while relying on external partnerships for CNS pipeline advancement.

Latest CYTOF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.